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ABSTRACT 
Purpose: To examine the effects of intensity and duration of exercise stress on induction of 
in-vivo immunity in humans using experimental contact hypersensitivity (CHS) with the 
novel antigen Diphenylcyclopropenone (DPCP). Methods: Sixty-four healthy males 
completed either 30 minutes running at 60% O2peak (30MI); 30 minutes running at 80% 
O2peak (30HI); 120 minutes running at 60% O2peak (120MI) or seated rest (CON). Twenty-
minutes later subjects received a sensitizing dose of DPCP and four-weeks later the strength 
of immune reactivity was quantified by measuring the cutaneous responses to a low, dose-
series challenge with DPCP on the upper inner-arm. Circulating epinephrine, norepinephrine 
and cortisol were measured pre, post and 1h post-exercise or CON. Next, to better understand 
whether the decrease in CHS response on 120MI was due to local inflammatory or T-cell 
mediated processes, in a cross-over design, eleven healthy males performed 120MI and CON 
and cutaneous responses to a dose-series of the irritant, croton oil (CO) were assessed on the 
upper inner-arm. Results: Immune induction by DPCP was impaired by 120MI (skin-fold-
thickness -67% vs CON; P<0.05).   However, immune induction was unaffected by 30MI and 
30HI despite elevated circulating catecholamines (30HI vs pre: P<0.01) and greater 
circulating cortisol post 30HI (vs CON: P<0.01). There was no effect of 120MI on skin 
irritant responses to CO. Conclusions: Prolonged, moderate-intensity exercise, but not short-
lasting high or short-lasting moderate-intensity exercise, decreases the induction of in-vivo 
immunity. No effect of prolonged, moderate-intensity exercise on the skin’s response to 
irritant challenge points towards a suppression of cell-mediated immunity in the observed 
decrease in CHS. DPCP provides an attractive tool to assess the effect of exercise on in-vivo 
immunity. 
Key words: stress; running; immune; contact hypersensitivity; diphencyprone; irritant 
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INTRODUCTION 
The skin constitutes the body’s largest immunological organ, providing the first line of defense 
against pathogenic and environmental assaults (8). Measures of in vivo immunity at the skin 
include delayed type hypersensitivity (DTH) responses to intradermal injection of antigens, or 
the less invasive contact hypersensitivity (CHS) responses to epicutaneous application of 
antigens. These in vivo measures are considered more informative than the commonly used in 
vitro measures where immune cells, typically from peripheral blood, are extracted from their 
normal environment and analyzed in artificial cultures (2). Isolated measures of immune 
function may react differently to a whole-body immune challenge because they lack the highly 
integrated neural and hormonal components within the specific tissue environment in which 
immune responses usually take place (1). Studies using in vivo cutaneous immune measures 
have shown impaired responses in individuals exposed to psychological stress (3), physical 
stress (17), during acute infectious illness e.g. Epstein-Barr virus (5) and in diabetes and 
psoriasis (4). Furthermore, in vivo cutaneous immune measures have been shown to predict 
mortality in critically ill HIV-infected patients (12) and in patients with surgical infections 
(31). There is a need to better understand in vivo cutaneous immune measures for investigators 
examining the influence of exercise stress on immunity in humans. 
Physical exercise provides a well-controlled model to study the effects of stress on immune 
responses. Given the obvious ethical constraints of studying experimental infection in humans, 
animal models have provided valuable insight into the effects of exercise on clinically relevant 
responses to viral infection. The work in animals indicates that prolonged and high intensity 
exercise is associated with higher mortality rates whereas short, moderate intensity exercise 
lowers mortality rates, compared with controls (21). The research evidence on immune 
responses after short, moderate intensity exercise in humans is not definitive and tends to 
indicate immune enhancement only in individuals with sub-optimal immune status (14, 30). 26 
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Work in humans indicating that a single bout of short duration, high intensity exercise and 
prolonged duration, moderate intensity exercise decreases immunity, is largely based upon 
results of studies examining in vitro immune measures (26, 32).  Little is known about the 
impact of a single bout of exercise on cutaneous measures of in vivo immunity in humans. One 
such study showed that after an acute bout of prolonged, continuous exercise (lasting ~6.5 h), 
DTH reactions to common recall antigens in the Mérieux CMI Multitest® were reduced but 
this test is no longer commercially available (6).  Moreover, the use of common recall antigens 
does not permit the assessment of the effects of stress on the induction of new immune 
memory and findings may be confounded by the lack of control over immunological memory: 
both the sensitizing dose and time elapsed since sensitization influence immunological 
memory. To the best of our knowledge, no study has investigated the impact of the intensity 
and duration of continuous exercise stress on in vivo immunity in humans. Challenging the skin 
using novel antigens such as keyhole limpet hemocyanin (KLH) (35) or 
diphenylcyclopropenone (DPCP) (17) permits the investigation of the influence of stressors on 
in vivo immunity and allows rigorous control of both the dose and timing of sensitization. 
Using topical DPCP, we have recently shown that 2 h of moderate intensity exercise decreases 
both the induction of immunity (-53%) in those with no prior exposure to DPCP and elicitation 
of immunity (-19%) in those who received repeated monthly DPCP exposures to boost 
responses to a reproducible plateau (17). Possible mechanisms include the activation of the 
hypothalamic-pituitary-adrenal axis and sympatheticoadrenal-medullary axis, which is widely 
acknowledged to occur following prolonged stress (typically lasting hours) and in-turn 
increases glucocorticoids and catecholamines, previously shown to decrease the induction of 
CHS in mice (10, 33). It has yet to be determined whether the inhibitory effects of prolonged 
exercise on immune responses to DPCP are due to systemic effects on the dendritic cell/T cell 
axis between the skin and lymph nodes or whether they involve local effects on cutaneous 
inflammatory processes mediated principally via innate immune mechanisms. The levels of 52 
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local cutaneous cytokines known to facilitate (e.g. IL-1β) and inhibit (e.g. IL-10) dendritic cell 53 
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(DC) migration are considered to play a central role in the early DC-dependent events of CHS 
induction, namely, antigen processing and DC trafficking (38). One experimental approach to 
this problem is to investigate the effect of prolonged, moderate intensity exercise on cutaneous 
responses to a topically applied irritant such as croton oil (CO). Unlike DPCP, which 
ultimately stimulates an antigen-specific, T-cell-mediated immune response, CO is an irritant, 
which stimulates a non-T-cell mediated, inflammatory response after a single exposure (27). 
CO has no sensitizing properties but is capable of producing similar cutaneous erythema 
responses to those seen after CHS challenge (40). 
Here we present the findings from two studies, starting with the effects of intensity and 
duration of exercise stress on in vivo immune induction by DPCP. We hypothesized that a 64 
prolonged, moderate intensity exercise bout (120 minutes at 60% V
.
O2peak) and a short, high 65 
intensity exercise bout (30 minutes at 80% V
.
O2peak) would decrease the CHS responses to 66 
DPCP compared with a short, moderate intensity exercise bout (30 minutes at 60% V
.
O2peak) 67 
and seated rest. Then, to examine whether exercise-related effects on local cutaneous 68 
inflammatory processes play a role in the inhibitory effect of prolonged, moderate intensity 69 
exercise on the CHS response we investigated irritant responses to a CO patch test. 70 
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METHODS 
Subjects. All subjects were healthy, non-smoking, recreationally active males with no previous 
history of exposure to DPCP. Subjects were excluded if they were taking any medication or 
dietary supplements, had a history of atopy or any other immune-related or inflammatory 
dermatological conditions. Subjects were required to abstain from caffeine, alcohol, and 
exercise for 24 h before and 48 h after the experimental trials. All subjects gave written 
informed consent to participate after being fully briefed and informed of the study’s 
procedures. The study received Local University Ethics Committee approval and was 
conducted in accordance with the Declaration of Helsinki principles. 
The effect of exercise intensity and duration on induction of DPCP immune memory.  
Subjects were matched for age and aerobic fitness (gas exchange threshold (GET) and O2peak) 
before being randomly assigned to one of four experimental groups: 1) 120 minutes of seated 
rest (CON); 2) 30 minutes of moderate intensity (60% O2peak) exercise (30MI); 3) 30 minutes 
of high intensity (80% O2peak) exercise (30HI); or  4) 120 minutes moderate intensity (60% 
O2peak) exercise (120MI) (Fig. 1). These exercise intensities and durations were chosen to 
allow comparison with the relevant literature (17), to assess the in vivo immune response to 
exercise recommended to healthy adults for fitness and health (e.g. the ACSM recommends 30 
minutes, moderate-intensity exercise on most days), to best separate intensity and duration 
effects on in vivo immunity; and finally, with feasibility in mind (e.g. our subjects could 
complete 30 minutes at 80% O2peak). There were no significant differences between groups 
for characteristics (Table 1). The study was performed between February, 2011 and April, 2012 
and no data was taken from our previous investigation that also included 120MI and CON 
trials (17).  95 
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*** Fig. 1 near here *** 96 
97 
*** Table 1 near here *** 98 
99 
Preliminary measures and familiarization. Anthropometric measures were recorded on 100 
arrival at the laboratory. Body composition assessment was completed by whole body Dual 101 
Energy X-ray Absorptiometry (DEXA: Hologic QDR Series-4500, USA). Following this, V
.
102 
O2peak was estimated by means of a ramped exercise test on a treadmill (h/p/cosmos Mercury 103 
4.0, Nussdorf-Traunstein, Germany). Following 3- minutes of walking at 5 km∙h-1 with an 104 
incline of 1 %, speed increased at a rate of 1 km∙h-1∙min-1 to a maximum of 18 km∙h-1, after 105 
which the incline increased at a rate of 1 %∙min-1 until volitional exhaustion. Pulmonary gas 106 
exchange was measured breath-by-breath for the duration of the test (Cortex Metalyser 3B, 107 
Biophysik, Leipzig, Germany). The V
.
O2peak was taken as the highest 30-s average value before 108 
the subject’s volitional exhaustion and the speed equivalent to 60 % or 80 % of the V
.
O2peak 109 
was calculated. The GET was also determined from the ramped exercise test using the V-slope 110 
method.  111 
112 
At least 24 h after the preliminary test, each subject’s calculated exercise intensity was verified 113 
by running for 50 % of their allocated exercise duration and all subjects were familiarized with 114 
laboratory equipment.  115 
116 
Experimental procedures. Dietary intake was controlled during the 24 h before the main 117 
experimental trial by providing subjects with their estimated daily energy requirement using 118 
DEXA determined fat free mass as described (mean ± SD: 11.2 ± 1.1 MJ day-1) (9), multiplied 119 
by a physical activity factor (37), and water proportional to 35 mL·kg-1·d-1 body mass.  120 
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Within 3 weeks of the preliminary testing, on the day of the exercise trial, all subjects were 
transported to the laboratory at 0730 h and provided with a standard breakfast (0.03 MJ·kg-1). 
Subjects were permitted to perform light activity before commencing the intervention. Nude 
body mass (NBM) was recorded before and after exercise on a digital platform scale to 
determine water allowance (Model 705; Seca, Hamburg, Germany). Exercising subjects 
received 5ml∙kg-1NBM of water immediately before and after the exercise, 2 ml∙kg-1NBM at 15 
minutes intervals throughout, and any additional exercise fluid loss was replaced following 
exercise. Subjects assigned to the 120MI began running on a treadmill at 1100 h and those 
assigned to 30HI and 30MI began at 1230 h, so that all subjects completed the exercise at the 
same time of day (1300 h; Fig. 1). Immediately after the trial, exercising subjects showered and 
returned to the laboratory within 15 minutes of completion. The CON, non-stress condition, 
consisted of 2 h seated, passive rest in the same laboratory, in the same ambient conditions of 
20 °C, at the same time of day, with a fluid intake proportional to 35 mL·kg-1·d-1 body mass. 
Induction of contact sensitivity. Subjects were sensitized to DPCP at 1320 h, exactly 20 
minutes after exercise cessation or equivalent seated rest, as described previously (17). This 
sensitization time was chosen to allow cutaneous blood flow to return to baseline (19). The 
sensitizing exposure to the novel antigen DPCP involved application of an occluded patch, 
constituting a 12 mm aluminum Finn chamber (Epitest Oy, Tuusula, Finland) on scanpor 
hypoallergenic tape containing an 11 mm filter paper disc. The paper disc was soaked in 22.8 
μl of 0.125  % DPCP in acetone (patch = 30 μg∙cm-2 DPCP) and allowed to dry for 5 minutes 
before being applied to the skin on the lower back, for exactly 48h.  
Elicitation. The magnitude of in vivo immune responsiveness was quantified by measuring the 
responses elicited by secondary exposure to the same antigen (Fig. 1). Twenty eight days after 
the initial sensitization to DPCP, all subjects received a challenge with a low concentration, 146 
9 
dose-series of DPCP on individual patches, each comprising an 8mm aluminium Finn chamber 147 
on scanpor hypoallergenic tape containing a 7 mm filter paper disc. Patches were applied to the 148 
inner aspect of the upper arm in the following concentrations: 10 μl of DPCP: 0.0048 %, 1.24 149 
μg∙cm-2; 0.0076 %, 1.98 μg∙cm-2; 0.012 %, 3.17 μg∙cm-2; 0.0195 %, 5.08 μg∙cm-2; 0.0313 %, 150 
8.12 μg∙cm-2 and 10 μl 100 % acetone control patch for background subtraction. Patches were 151 
applied in randomly allocated order at the local site in order to minimize any anatomical 152 
variability in responses. Elicitation patches were removed after 6 h and the strength of immune 153 
reactivity was assessed as cutaneous responses at 48 h post-application. 154 
155 
Blood collection and analysis. Blood samples (venepuncture from an antecubital vein) were 156 
collected into one K3EDTA coated vacutainer, and one lithium heparin coated vacutainer 157 
(Becton Dickinson, Oxford, UK) pre, immediately post and 1 h post exercise. The samples 158 
were spun at 1500 g for 10 minutes in a refrigerated centrifuge. Plasma was aliquoted into 159 
Eppendorf tubes, and immediately frozen at -80C for later analysis.   160 
161 
Plasma epinephrine and norepinephrine concentrations in K3EDTA plasma were determined 162 
using a commercially available CatCombi ELISA (IBL International, Hamburg, Germany). 163 
Aliquots of lithium heparin plasma were used to determine cortisol concentration by ELISA, 164 
performed according to the manufacturer’s instructions (DRG Instruments, Marburg, 165 
Germany).  The intra-assay coefficient of variation for plasma epinephrine, norepinephrine and 166 
cortisol was 4.1 %, 4.1 % and 4.4 %, respectively.  167 
168 
The effect of prolonged, moderate intensity exercise on the cutaneous response to the 169 
irritant, croton oil. To investigate the possibility that the inhibitory effect of 120MI on CHS 170 
induction was mediated via local effects on cutaneous inflammatory processes, 11 healthy 171 
10 
males (age 24 ± 5 years; height 179 ± 8 cm; body mass 79.0 ± 9.9 kg;  V
.
O2peak 53 ± 6 ml.kg
-172 
1.min-1) completed a follow-up study to investigate the cutaneous responses to the non-specific 173 
irritant, CO. 174 
175 
In a randomized, counterbalanced, repeated measures design, subjects performed 120MI-CO or 176 
CON-CO separated by 7 - 14 d. Subjects received a CO challenge at 1320 h, exactly 20 177 
minutes after exercise cessation or seated rest. This involved the topical application of a dose-178 
series of CO on individual patches comprising 8mm aluminium Finn chambers mounted on 179 
hypoallergenic scanpor tape and 7 mm filter paper discs. Patches were applied in duplicate to 180 
the inner aspect of the upper arm in the following concentrations: 10 µl of CO in ethanol: 0.3 181 
%, 0.55 %, 1.0 % and 3 % and 10 µl 100 % ethanol control patch (23). To account for local 182 
anatomical variability, the location of each concentration was randomized. Patches remained in 183 
place for exactly 24 h and the assessment of cutaneous responses was performed 2 h after 184 
removal of the CO patches, as described (23).  185 
186 
Assessment of cutaneous responses. Skin edema (inflammatory swelling) is considered the 187 
key measure of CHS elicitation responses (17). This was assessed as mean skin-fold thickness 188 
from triplicate measurements at each elicitation site using modified spring-loaded skin callipers 189 
(Harpenden Skin-fold Calliper, British Indicators, England), as described (17). Skin-fold 190 
thickness was recorded to the nearest 0.1 mm by the same investigator by placing the jaws of 191 
the calliper at the outer diameter of the response site and measuring skin thickness only (no 192 
subcutaneous fat).  193 
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Dermal thickness was determined at each patch site using a high-frequency ultrasound scanner 
(Episcan, Longport Inc., Reading, UK). The ultrasound probe was placed over the centre of 
each patch site together with ultrasound gel. The mean of three measurements was taken from 
each 12 mm scan image by an independent investigator, who was blinded to the trial 
assignment. Due to a delay in the availability of this equipment, dermal thickness was assessed 
in a subpopulation of 50 subjects who completed the DPCP patch test (CON = 13, 30MI = 14, 
30HI = 12, 120MI = 11) and all subjects who completed the CO patch test. 
Skin erythema is an objective measure of skin redness, which is considered the key measure of 
irritant responses (29). This was determined from triplicate measurement at each patch site 
using an erythema meter (ColorMeter DSM11, Cortex Technology, Hadsund, Denmark) as 
previously described (17).  
Mean background values were determined from triplicate measurements at the vehicle only 
patch site for thickness and redness. In order to determine the increase in thickness and redness 
in response to DPCP or CO, the value from the vehicle-only site was subtracted from each 
patch site value. The values for increase in skin-fold thickness, dermal thickness and erythema 
over all the doses were summed, which gave an approximation of the area under the dose-
response curve, representative of the overall reactivity of each subject to DPCP or CO, 
respectively. 
Statistical analysis. Data in the results are presented as mean ± SD, unless otherwise stated 
and statistical significance was accepted at P < 0.05. Data were checked for normality and 
sphericity. Greenhouse-Geisser adjustments to the degrees of freedom were applied where 
necessary (skin-fold dose-series response to DPCP, epinephrine, norepinephrine and cortisol). 219 
12 
All statistical analysis was conducted using SPSS software. The mean difference with 95 % 220 
confidence intervals is presented for the main outcome measures. 221 
222 
Sample size was estimated using data from a previous study examining the effect of prior 223 
exercise stress on CHS responses to DPCP (17). The alpha (Type I error rate) was set at 0.05, 224 
and power at 0.95 (1 - Type II error rate) (G*Power software, version 3.1.2). For the CO 225 
element, a minimum important difference using biological variation data of the summed CO 226 
227 
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242 
erythema response was used to estimate an effect size (0.91). A one-way ANOVA was used to 
assess differences between the groups in physical characteristics. The effect of exercise 
intensity and duration was analyzed using a one-way ANOVA to determine differences in the 
summed increase in responses to DPCP between the CON, 30MI, 30HI and 120MI trials. A 
two-way, mixed model ANOVA (DPCP data) or a repeated measures ANOVA (CO data) was 
used to analyze the skin-fold and dermal thickness responses across the full dose-series 
challenge (trial × dose). A two-way mixed model ANOVA (trial × time) was used to compare 
the circulating stress hormone data. Significant differences were identified using post hoc 
Tukeys HSD or Bonferroni corrected t-tests, where appropriate. To further investigate the 
differences between CON and 120MI, independent t-tests (DPCP data) or paired t-tests (CO 
data) were used to assess summed increases. Logarithmic transformation was performed on 
the DPCP data to allow for the calculation of the x-intercept when y = 0, utilizing linear 
regression on the linear portion of the dose response curve. A threshold dose for a response to 
DPCP was then calculated by back transformation (anti-log). Simple linear regression and a 
calculation of the standard error of the estimate (SEE) were performed to assess the validity of 
skin-fold measurement, using skin-fold callipers, as a practical method to determine dermal 
thickening compared with the objective criterion, high-frequency ultrasound. This was 
performed on the 
243 
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tes for a sub-population with complete data sets at the 48 h time point 244 sum of the 5 elicitation si 
(n=50).  245 
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RESULTS 
The effect of exercise intensity and duration on induction of DPCP immune memory.  
Assessment of CHS responses. The skin-fold response, summed from five challenge doses, 
was significantly different between groups (F(3,60) = 3.6, P < 0.05). Tukeys post hoc analysis 
revealed that skin-fold thickness was reduced 67% by 120MI compared with CON (P < 0.05; 
Fig. 2a). The mean difference between 120MI and CON was 3.17 mm (95% confidence 
intervals 0.31 to 6.03 mm). There was no significant difference between the short duration 
30MI or 30HI exercise groups compared with CON. The full, dose-series response to DPCP 
for each group was also determined for the increase in skin-fold thickness (Fig. 2b). The skin-
fold thickness responses from the five individual doses revealed a significant trial × dose 
interaction (F(7.3,145.1) = 3.0, P < 0.01). Post hoc analysis revealed that skin-fold thickness 
was significantly lower in 120MI compared with CON at the 1.98 µg·cm-2 dose (P < 0.05), 
5.08 µg·cm-2 and 8.12 doses (P < 0.01) and approached significance at the 3.17 µg·cm-2 dose 
(P = 0.058). To further investigate the differences between CON and 120MI, the threshold 
dose for a positive response to DPCP was calculated using the linear part of the dose response 
curve, as 0.48 and 2.09 µg·cm-2 for the CON and 120MI groups, respectively. This suggests 
that to elicit a positive response, 120MI required a 4.4 times greater DPCP dose in 
comparison with CON. Skin-fold thickness assessed using skin-fold callipers was strongly 
related with high-frequency ultrasound readings of dermal thickness (r = 0.93, r2 = 0.86, SEE 
= 1.3 mm; P < 0.01).  
*** Fig. 2 near here*** 
Circulating stress hormones. At baseline, pre-exercise, there were no significant differences 
between groups for circulating epinephrine, norepinephrine or cortisol concentration. A 
significant trial × time interaction was observed for circulating epinephrine (F(4.6,88.5) = 7.0, 272 
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P < 0.01; Fig. 3a), norepinephrine (F(3.4,67.1) = 24.0, P < 0.01; Fig. 3b) and cortisol 
concentration (F(4.6,90.6) = 7.0, P < 0.01; Fig. 3c). The raised circulating epinephrine and 
norepinephrine concentration observed immediately post on both 120MI and 30HI (P < 0.01) 
had returned to pre-exercise levels by 1 h post exercise. Circulating epinephrine concentration 
was greater at post on 120MI compared with CON (P < 0.01) and circulating norepinephrine 
concentration was greater at post on 30HI compared with CON (P < 0.01). Circulating cortisol 
concentration was greater at post and 1 h post on 120MI and at post on 30HI compared with 
CON (P < 0.01). The typical diurnal response in circulating cortisol concentration is shown, 
whereby levels were lower at post (1300) and 1 h post (1400) compared with pre-exercise 
(1100) on both 30MI and CON (P < 0.01).  
*** Fig. 3 near here *** 
The effect of prolonged, moderate intensity exercise on the induction of DPCP immune 
memory and cutaneous responses to the irritant, croton oil.  
The aim here was to examine whether the inhibitory effect of 120MI on CHS is due to local 
effects on cutaneous inflammatory processes mediated principally via innate immune 
mechanisms. To this end, Fig. 4 shows the summed responses to all challenge doses for 
induction of DPCP immune memory (5 doses) and irritant responses to CO (4 doses). Results 
are presented as dermal thickness, considered a key measure of CHS responses (17), and 
erythema, considered a key measure of irritant responses (29). Here we show that 120MI 
significantly decreased DPCP responses measured as dermal thickness (t(22) = 3.5, P < 0.01; 
Fig. 4b) and erythema (t(30) = 2.1, P < 0.05; Fig. 4a). The mean difference for dermal 
thickness was 3.17 mm (95% confidence intervals 1.27 to 5.07) and for erythema was 18.61 
AU (95% confidence intervals 0.41 to 36.82). No effect of 120MI-CO on irritant responses 297 
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305 
306 
307 
308 
309 
310 
measured as erythema (t(10) = 0.2, P = 0.826; Fig. 4c) or dermal thickness (t(10) = 1.2, P = 
0.253; Fig. 4d) points to an inhibitory effect of 120MI on cell-mediated processes rather than 
local inflammatory processes in the decrease in CHS. It is noteworthy that the erythematous 
response to the top challenge dose of CO was comparable to the erythematous response to the 
top dose of DPCP (mean ± SD: 11.75 ± 5.28 AU and 11.25 ± 4.84 AU, respectively). As would 
be expected, dermal thickening response to the dose-series of the irritant, CO was small 
compared with DPCP (Fig. 4 d). For visual comparison, the increase in erythema responses to 
the full, dose-series of CO is also presented (Fig. 5). There was no significant trial × dose 
interaction observed between 120MI-CO and CON-CO for erythema responses (F(3,30) = 1.4, 
P = 0.267). 
***Fig. 4 near here *** 
***Fig. 5 near here *** 311 
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343 
DISCUSSION 
The advantages of, and the need for further research utilizing, in vivo immune measures in 
humans have recently been highlighted (1, 39). The primary aim of this work was to determine 
the unknown effects of the intensity and duration of continuous exercise stress on the induction 
of in vivo immunity in humans. In line with our hypothesis, prolonged, moderate intensity 
exercise (120MI) decreased the induction of in vivo immunity; however, short lasting moderate 
intensity (30MI) or high intensity (30HI) exercise did not influence this response despite 
elevated circulating catecholamines on 30HI and greater circulating cortisol on 30HI compared 
with CON. We then demonstrated that prolonged exercise had no effect on cutaneous 
responses to the irritant, CO. These findings support the notion that the observed decrease in in 
vivo immune induction to DPCP represents an effect on T-cell mediated immune responses 
rather than exercise-effects on local expression of inflammatory effector processes. 
This is the first study to compare the effects of intensity and duration of continuous exercise 
stress on in vivo immunity assessed by use of an experimental CHS model in humans. In 
keeping with our previous findings, we observed that 120MI had a significant inhibitory effect 
on the induction of new immunity via the skin (17). Our finding that 30MI had no effect on in 
vivo immune induction is at odds with one hypothesis underpinning the J-shaped model (25), 
whereby a moderate dose of exercise is proposed to be immune-enhancing, but in accordance 
with recent research showing no effect of a moderate dose of exercise on the response to 
vaccination in young, healthy adults (20). While other studies have shown that a moderate dose 
of exercise can enhance antibody responses to vaccination, thereby supporting one hypothesis 
underpinning the J-shaped model, this typically occurs in individuals with sub-optimal immune 
status or when a half dose of vaccine is administered (14, 30). We also acknowledge that 344 
18 
exercise might differentially affect CHS, a cutaneous T-cell mediated response, and the 345 
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antibody response to vaccination, a systemic B-cell mediated response. 
We hypothesized that 30HI would decrease in vivo immune induction to DPCP, based upon 
evidence from in vitro work showing that short lasting high intensity exercise decreases 
indicators of both lymphocyte and neutrophil function (26, 32). However, our results do not 
support this despite elevated circulating catecholamines on 30HI and greater circulating 
cortisol on 30HI compared with CON. These findings provide little support for an involvement 
of circulating stress hormones in the mechanisms associated with altered in vivo immune 
responses to DPCP at the skin. For example, circulating norepinephrine was highest after 30HI 
when there was no immunosuppression suggesting that circulating norepinephrine has little 
immunosuppressive effect on the CHS system. Although circulating cortisol tended to be 
higher on 120MI compared with 30HI this did not reach statistical significance. In addition, 
circulating cortisol exceeded the purported binding capacity (~552 nmol·L-1)(22) at post-
exercise before DPCP application in a similar proportion of subjects on 30HI (11 of 16) and 
120MI (12 of 16) yet 30HI did not decrease immune induction by DPCP. There is clear 
evidence from murine models that high doses of these stress hormones can have significant 
immune-modulating effects. Intradermal injections of high dose corticosterone or 
catecholamines, both locally or distant from the sensitization site, inhibit the antigen-presenting 
capability of cutaneous DCs, reduce the number of T cells in draining lymph nodes and 
ultimately suppress DTH and CHS responses (11, 15, 33).  Results from human studies are less 
consistent with some authors reporting a lack of association between stress hormones and in 
vivo immune responses (3, 13, 28). One frequently proposed explanation is that human studies 
typically rely on individual snapshot assessments of circulating stress hormones, thus missing 
important information regarding the kinetics of these responses. In this regard, we 369 
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385 
acknowledge a limitation of the current study is that we applied the DPCP sensitization patch 
20 minutes after exercise at a time when circulating cortisol likely reached a peak but 
circulating catecholamines would likely have returned to pre-exercise levels. At the outset, we 
considered the strengths and weaknesses of DPCP sensitization at the cessation of exercise to 
coincide with the peak in circulating catecholamines. After careful consideration, we chose to 
delay sensitization until 20 minutes after exercise to avoid possible confounding due to raised 
skin blood flow and sweating. One might also argue that another limitation is that we only took 
blood samples to characterize circulating cortisol at immediately post and 1 h post exercise yet 
the DPCP sensitizing patch remained in place for 48 h. Work in young adults showed the 
inhibitory effect of stress on the development of immune memory is particularly evident when 
stress is experienced at, or close to, the time of sensitization: this supports our choice of sample 
timing to characterize the circulating cortisol response in close proximity to the exercise stress 
(35).  
The findings from the current study show that 120MI had no impact on cutaneous 
inflammatory responses to CO. This suggests that the inhibitory effect of 120MI on CHS 
induction with DPCP is likely associated with cell-mediated events rather than exercise effects 386 
387 
388 
389 
390 
391 
392 
393 
on local inflammatory processes. Further research is required to better understand the 
mechanisms associated with the inhibitory effect of 120MI on in vivo responses to DPCP. 
Research should target the interactions between DC’s and T cells in terms of antigen 
processing and presentation and activation of T cells and the subsequent balance between 
effector and regulatory T cells considered central to the successful induction of CHS (38). 
Also, the duration of the inhibitory effect of prolonged, heavy exercise on CHS induction in 
humans remains unknown and could be determined in a study that manipulates the timing of 
DPCP sensitization after 120MI. Given the reported sex differences in immune responses to 394 
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exercise (16), we recognize the limitation of using only males in this study and encourage the 395 
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investigation of in vivo immune responses to exercise using this CHS model in females. 
Experimental-CHS provides an attractive measure of in vivo immunity, not only because the 
skin is immediately accessible but because it overcomes many of the limitations of commonly 
used in vitro measures which are lacking in terms of clinical significance and practicality. We 
recognize that there are limitations with using DPCP in the CHS model described. Given that 
DPCP is benign, determining the clinical significance of the response, with specific regard to 
infection (skin and other) is an important avenue for future research. Preferably, the strength of 
the cutaneous recall response to DPCP could be generalized beyond skin immunity to indicate 
the immune system’s general ability to respond to an infectious challenge. The available 
evidence in this regard is supportive as cutaneous immune measures are impaired in 
individuals with acute infectious illness (5), diabetes and psoriasis (4), and predict mortality in 
critically ill HIV-infected patients (12). An alternative viewpoint is that the benign 
characteristic of DPCP actually overcomes the ethical constraints associated with using live 
pathogens, such as rhinovirus to assess in vivo immunity. We also recognize the limitation that 
experimental-CHS requires purposefully inducing CHS; nevertheless, the selected doses we 
use are low and the mild elicitation responses are temporary. 
Experimental-CHS with DPCP is practical, safe, and can be administered without the need for 
expensive equipment, invasive injections or blood sampling, making it a suitable 
immunological tool for both laboratory and field investigations. Moreover, the use of a novel 
antigen such as DPCP provides investigators with rigorous control over the timing and dose of 
sensitizing exposure, enabling the effects of various stressors on the primary immune response 
to be studied. The measurement of DTH responses to KLH is an alternative per-cutaneous in 419 
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vivo method, also reported to represent a primary immune response (36).  However, since KLH 
is derived from a shellfish this may explain why some individuals exhibit significant responses 
to KLH prior to immunization (34). Experimental-CHS with DPCP is not restricted to 
examining the effects of stress on the induction phase. Recently we have shown that this 
approach can be used to assess the effect of exercise stress on the elicitation phase in subjects 
who, following repeated monthly DPCP skin challenges, achieved a reproducible plateau in 
responses (17). Furthermore, the standardized CHS model we describe overcomes some of the 
limitations of vaccine models of in vivo immunity including variable immunogenicity (e.g. 
hepatitis B (18)), annual changes in vaccine (e.g. influenza (7)) and difficulty when comparing 
the circulating antibody results from different studies using in-house ELISAs. Nevertheless, a 
standard protocol for measuring CHS elicitation responses in humans has yet to be established. 
The use of erythema to quantify CHS elicitation has been questioned, particularly at sites of 
stronger responses, where yellow vesicles can interfere with the erythema (redness) readings 
(17, 24). Erythema is typically the preferred measure of irritant responses which, as we show 
(Fig. 4 d), induce less edema than CHS responses (29). Notwithstanding the degree of 
subjectivity, a particular strength of the current findings is that skin-fold thickness was 
strongly related with dermal thickness measured by a high-frequency ultrasound scanner and 
read by a blinded investigator (r = 0.93). Hence, we agree with the recommendation of others 
that, skin-fold callipers present a simple and cost-effective measure of CHS edema (24).  
In conclusion, using experimental CHS with DPCP, these results demonstrate that prolonged, 
moderate intensity exercise, but not short-lasting high or short-lasting moderate intensity 441 
exercise, decreases the induction of in vivo immunity in healthy humans. No effect of 442 
prolonged, moderate intensity exercise on the skin’s response to the irritant, CO points towards 443 
a suppression of cell-mediated immunity in the observed decrease in CHS response. The 444 
22 
topical application of DPCP provides an attractive tool to assess the effect of exercise stress on 445 
in vivo immunity in humans.   446 
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Figure Legends 
FIGURE 1. Schematic for the effect of exercise intensity and duration on induction of DPCP 
immune memory. Samples; venepuncture blood. 
FIGURE 2. Effect of exercise stress prior to induction of contact hypersensitivity with DPCP 
on responses to elicitation challenge 28 d later. Shown here as (a) summed increase in skin-
fold thickness (callipers: mean ± SD) and (b) responses to the full dose-series challenge with 
DPCP 
573 
on skin-fold thickness (callipers: mean ± SEM) # P < 0.05 and ## P < 0.01 vs CON.574 
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FIGURE 3. Circulating epinephrine (a), norepinephrine (b) and cortisol (c) response to 
exercise or seated rest. ↓= induction of contact sensitivity by DPCP application. ** P < 0.01 vs 
pre-exercise; ## P < 0.01 vs CON. Data are mean ± SEM. 
FIGURE 4. Effect of prolonged exercise stress (120MI) or seated rest (CON) prior to induction 
of contact sensitivity with DPCP or irritant challenge with CO. Shown here are the summed 
responses to: DPCP elicitation challenge 28 d later, measured as (a) erythema and (b) dermal 
thickness (ultrasound); and CO challenge applied 20 minutes after exercise or equivalent seated 
rest, measured as (c) erythema and (d) dermal thickness (ultrasound). # P < 0.05 and ## P < 
0.01 vs CON. Data are mean ± SD. 
FIGURE 5. Effect of prolonged exercise stress (120MI-CO) or seated rest (CON-CO) on 
erythema responses to irritant challenge with CO. Shown here are the responses to the full 589 
27 
nutes after exercise or equivalent seated rest. Data 590 dose-series challenge with CO applied 20 mi 
are mean ± SEM. 591 
592 
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TABLE 1. Subject information. Values are mean ± SD. 594 
CON 30MI 30HI 120MI 
N 
Age (years) 
Height (cm) 
Body mass (kg) 
Body fat (%) 
VO2peak (ml·kg
-1·min-1) 
GET (L·min-1) Weekly 
exercise (h) 
16 
23 ± 4 
180 ± 7 
77.3 ± 11.3 
15.2 ± 3.7 
57 ± 7 
3.04 ± 0.31 
6 ± 4 
16 
20 ± 2 
180 ± 5 
74.5 ± 10.1 
15.1 ± 4.5 
58 ± 5 
3.09 ± 0.59 
6 ± 2 
16 
22 ± 4 
179 ± 7 
76.3 ± 12.8 
15.0 ± 4.7 
58 ± 6 
3.08 ± 0.60 
5 ± 2 
16 
22 ± 4 
 180 ± 7 
78.8 ± 12.1
15.9 ± 4.3 
56 ± 5 
3.11 ± 0.51 
6 ± 3 
GET, gas exchange threshold 595 
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